◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Essex Bio-Technology Limited (1061) Financial History

Name: Essex Bio-Technology Limited (1061) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-10

Essex Bio-Technology Limited (1061) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Zhuhai, China with about 1,289 employees. Its market capitalization is roughly HKD 1 billion. In the fiscal year ended 2025-12-31, 1061 reported HKD 1.8B in revenue and HKD 318M in net income.

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. It operates through Ophthalmology, Surgical, and Healthcare and Partner Services segments.

Interactive charts & full statements →

1061 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	HKD 1.8B	HKD 1.7B	HKD 1.7B	HKD 1.3B	—
Gross Profit	HKD 1.6B	HKD 1.5B	HKD 1.6B	HKD 1.2B	—
Operating Income (EBIT)	HKD 414M	HKD 355M	HKD 334M	HKD 282M	—
Net Income	HKD 318M	HKD 307M	HKD 275M	HKD 225M	—

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1061 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(HKD 74M)	(HKD 60M)	(HKD 40M)	(HKD 54M)	—

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1061 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	HKD 3.5B	HKD 3.0B	HKD 2.8B	HKD 2.7B	—
Total Liabilities	HKD 1.1B	HKD 859M	HKD 904M	HKD 981M	—

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1061 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

2161 · JBM (Healthcare) Limited — $2 billion
HROW · Harrow, Inc. — $2 billion
2348 · Dawnrays Pharmaceutical (Holdings) Limited — $1 billion
PPGN · PolyPeptide Group AG — $1 billion
PAHC · Phibro Animal Health Corporation — $1 billion
ALVO · Alvotech — $1 billion
XERS · Xeris Biopharma Holdings, Inc. — $1 billion
CRON · Cronos Group Inc. — $1 billion

← 1060 All “0-9” companies 1063 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.